Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Jul;157(1):128-136.e5.
doi: 10.1053/j.gastro.2019.03.015. Epub 2019 Mar 11.

A Diet Low in Red and Processed Meat Does Not Reduce Rate of Crohn's Disease Flares

Affiliations
Randomized Controlled Trial

A Diet Low in Red and Processed Meat Does Not Reduce Rate of Crohn's Disease Flares

Lindsey Albenberg et al. Gastroenterology. 2019 Jul.

Abstract

Background & aims: Diet may be an important factor in the progression of Crohn's disease (CD). We performed a randomized controlled trial to determine whether reduced consumption of red and processed meats decreases the risk of symptomatic relapse of CD, analyzing results from the Food and Crohn's Disease Exacerbation Study (FACES) trial.

Methods: Adults with CD were recruited into the FACES trial from IBD Partners, an Internet-based cohort of patients with inflammatory bowel disease, from November 2013 through June 2015. Individuals who were in remission (CD activity index [sCDAI] scores of ≤150), had completed a biannual survey, and reported consumption of red meat at least once weekly were randomly assigned to groups that consumed a minimum of 2 servings/week of red or processed meat (high meat, n = 118) or not more than 1 serving per month (low meat, n = 96) for 49 weeks. The primary outcome was relapse of CD, defined as increase in sCDAI score by ≥70 points and to >150 or a need for CD surgery or new CD medication. A secondary outcome, moderate or severe relapse, was based on an increase in sCDAI to >219.

Results: During the trial, the high-meat groups reported consumption of 2 or more servings of red or processed meat during 98.5% of observed weeks compared with 18.8% of weeks for the low-meat group. Any and moderate to severe relapse occurred in 62% of participants in the high-meat group and 42% of participants in the low-meat group. There were no significant differences in time to any (P = .61) or moderate/severe (P = .50) relapse.

Conclusions: In an analysis of data from the FACES trial, we found that among patients with CD in remission, level of red and processed meat consumption was not associated with time to symptomatic relapse. ClinicalTrials.gov, Number: NCT0192673.

Trial registration: ClinicalTrials.gov NCT00192673.

Keywords: IBD; Inflammatory Bowel Disease; Prevention; Quiescent Disease.

PubMed Disclaimer

Conflict of interest statement

Potential Conflicts of Interest:

Dr. Albenberg has received research funding from Seres Therapeutics.

Dr. Lewis has served as a consultant for: Nestle Health Science, Johnson & Johnson Consumer Inc, Janssen Pharmaceuticals, Takeda, AbbVie, Merck, Celgene, Eli Lilly and Company, Samsung Bioepis, Pfizer, Gilead, UCB, Arena Pharmaceuticals and Bridge Biotherapeutics. He has received research funding from Nestle Health Science, Takeda, and Janssen.

Dr. Kappelman has received research funding from and serves as a consultant for Johnson & Johnson Consumer Inc, Abbvie, Pfizer, and Eli Lilly. He is a shareholder to Johnson & Johnson Consumer Inc.

Figures

Figure 1
Figure 1
FACES CONSORT diagram
Figure 2
Figure 2
Dietary pattern before and after the intervention a. Principle component analysis of baseline dietary patterns using nutrient variables b. Principle component analysis of baseline dietary patterns using whole foods variables
Figure 3
Figure 3
Comparison of time to symptomatic relapse by arm a. Time to any symptomatic relapse b. Time to moderate to severe symptomatic relapse c. Time to persistent symptomatic relapse
Figure 4
Figure 4
a. Comparison of adherence to the diet by treatment arm. The high meat group consumed 2+ servings of red or processed meat in 98.5% of weeks. The low meat group consumed 0 servings red or processed meat in 57.3% of weeks. b. Percent of weeks that participants in each treatment group reported consuming two or more portions of red or processed meats c. Change in consumption of red meat from baseline to week 20 by treatment arm

Similar articles

  • Saccharomyces boulardii does not prevent relapse of Crohn's disease.
    Bourreille A, Cadiot G, Le Dreau G, Laharie D, Beaugerie L, Dupas JL, Marteau P, Rampal P, Moyse D, Saleh A, Le Guern ME, Galmiche JP; FLORABEST Study Group. Bourreille A, et al. Clin Gastroenterol Hepatol. 2013 Aug;11(8):982-7. doi: 10.1016/j.cgh.2013.02.021. Epub 2013 Mar 1. Clin Gastroenterol Hepatol. 2013. PMID: 23466709 Clinical Trial.
  • Comparing Two Diets to Decrease Symptoms from Crohn's Disease – The DINE-CD Study [Internet].
    Lewis JD, Sandler R, Brotherton C, Brensinger C, Li H, Kappelman MD, Daniel SG, Bittinger K, Albenberg L, Valentine JF, Hanson J, Suskind D, Meyer A, Compher CW, Bewtra M, Saxena A, Dobes A, Cohen B, Flynn AD, Fischer M, Saha S, Swaminath A, Yacyshyn B, Scherl E, Horst S, Curtis JR, Braly K, Nessel L, McCauley M, McKeever L, Herfarth H; DINE-CD Study Group. Lewis JD, et al. Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2021 Oct. Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2021 Oct. PMID: 39312597 Free Books & Documents. Review.
  • Lifestyle-related disease in Crohn's disease: relapse prevention by a semi-vegetarian diet.
    Chiba M, Abe T, Tsuda H, Sugawara T, Tsuda S, Tozawa H, Fujiwara K, Imai H. Chiba M, et al. World J Gastroenterol. 2010 May 28;16(20):2484-95. doi: 10.3748/wjg.v16.i20.2484. World J Gastroenterol. 2010. PMID: 20503448 Free PMC article. Clinical Trial.
  • Association of ultra-processed food intake with risk of inflammatory bowel disease: prospective cohort study.
    Narula N, Wong ECL, Dehghan M, Mente A, Rangarajan S, Lanas F, Lopez-Jaramillo P, Rohatgi P, Lakshmi PVM, Varma RP, Orlandini A, Avezum A, Wielgosz A, Poirier P, Almadi MA, Altuntas Y, Ng KK, Chifamba J, Yeates K, Puoane T, Khatib R, Yusuf R, Boström KB, Zatonska K, Iqbal R, Weida L, Yibing Z, Sidong L, Dans A, Yusufali A, Mohammadifard N, Marshall JK, Moayyedi P, Reinisch W, Yusuf S. Narula N, et al. BMJ. 2021 Jul 14;374:n1554. doi: 10.1136/bmj.n1554. BMJ. 2021. PMID: 34261638 Free PMC article.
  • Antibiotics for induction and maintenance of remission in Crohn's disease.
    Townsend CM, Parker CE, MacDonald JK, Nguyen TM, Jairath V, Feagan BG, Khanna R. Townsend CM, et al. Cochrane Database Syst Rev. 2019 Feb 7;2(2):CD012730. doi: 10.1002/14651858.CD012730.pub2. Cochrane Database Syst Rev. 2019. PMID: 30731030 Free PMC article.

Cited by

References

    1. Ananthakrishnan AN. 2013. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (N Y) 9:367–74. - PMC - PubMed
    1. Lochs H, Dejong C, Hammarqvist F, Hebuterne X, Leon-Sanz M, Schutz T, van Gemert W, van Gossum A, Valentini L, Lubke H, Bischoff S, Engelmann N, Thul P. 2006. ESPEN Guidelines on Enteral Nutrition: Gastroenterology. Clin Nutr 25:260–74. - PubMed
    1. Sandhu BK, Fell JM, Beattie RM, Mitton SG, Wilson DC, Jenkins H. 2010. Guidelines for the Management of Inflammatory Bowel Disease in Children in the United Kingdom. J Pediatr Gastroenterol Nutr doi:10.1097/MPG.0b013e3181c92c53. - DOI - PubMed
    1. Riordan AM, Hunter JO, Cowan RE, Crampton JR, Davidson AR, Dickinson RJ, Dronfield MW, Fellows IW, Hishon S, Kerrigan GN, et al. 1993. Treatment of active Crohn’s disease by exclusion diet: East Anglian multicentre controlled trial. Lancet 342:1131–4. - PubMed
    1. Bartel G, Weiss I, Turetschek K, Schima W, Puspok A, Waldhoer T, Gasche C. 2008. Ingested matter affects intestinal lesions in Crohn’s disease. Inflamm Bowel Dis 14:374–82. - PubMed

Publication types

Associated data